HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Automated iterative neutrosophic lung segmentation for image analysis in thoracic computed tomography.

AbstractPURPOSE:
Lung segmentation is a fundamental step in many image analysis applications for lung diseases and abnormalities in thoracic computed tomography (CT). The authors have previously developed a lung segmentation method based on expectation-maximization (EM) analysis and morphological operations (EMM) for our computer-aided detection (CAD) system for pulmonary embolism (PE) in CT pulmonary angiography (CTPA). However, due to the large variations in pathology that may be present in thoracic CT images, it is difficult to extract the lung regions accurately, especially when the lung parenchyma contains extensive lung diseases. The purpose of this study is to develop a new method that can provide accurate lung segmentation, including those affected by lung diseases.
METHODS:
An iterative neutrosophic lung segmentation (INLS) method was developed to improve the EMM segmentation utilizing the anatomic features of the ribs and lungs. The initial lung regions (ILRs) were extracted using our previously developed EMM method, in which the ribs were extracted using 3D hierarchical EM segmentation and the ribcage was constructed using morphological operations. Based on the anatomic features of ribs and lungs, the initial EMM segmentation was refined using INLS to obtain the final lung regions. In the INLS method, the anatomic features were mapped into a neutrosophic domain, and the neutrosophic operation was performed iteratively to refine the ILRs. With IRB approval, 5 and 58 CTPA scans were collected retrospectively and used as training and test sets, of which 2 and 34 cases had lung diseases, respectively. The lung regions manually outlined by an experienced thoracic radiologist were used as reference standard for performance evaluation of the automated lung segmentation. The percentage overlap area (POA), the Hausdorff distance (Hdist), and the average distance (AvgDist) of the lung boundaries relative to the reference standard were used as performance metrics.
RESULTS:
The proposed method achieved larger POAs and smaller distance errors than the EMM method. For the 58 test cases, the average POA, Hdist, and AvgDist were improved from 85.4±18.4%, 22.6±29.4 mm, and 3.5±5.4 mm using EMM to 91.2±6.7%, 16.0±11.3 mm, and 2.5±1.0 mm using INLS, respectively. The improvements were statistically significant (p<0.05). To evaluate the accuracy of the INLS method in the identification of the lung boundaries affected by lung diseases, the authors separately analyzed the performance of the proposed method on the cases with versus without the lung diseases. The results showed that the cases without lung diseases were segmented more accurately than the cases with lung diseases by both the EMM and the INLS methods, but the INLS method achieved better performance than the EMM method in both cases.
CONCLUSIONS:
The new INLS method utilizing the anatomic features of the rib and lung significantly improved the accuracy of lung segmentation, especially for the cases affected by lung diseases. Improvement in lung segmentation will facilitate many image analysis tasks and CAD applications for lung diseases and abnormalities in thoracic CT, including automated PE detection.
AuthorsYanhui Guo, Chuan Zhou, Heang-Ping Chan, Aamer Chughtai, Jun Wei, Lubomir M Hadjiiski, Ella A Kazerooni
JournalMedical physics (Med Phys) Vol. 40 Issue 8 Pg. 081912 (Aug 2013) ISSN: 2473-4209 [Electronic] United States
PMID23927326 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Topics
  • Automation
  • Humans
  • Image Processing, Computer-Assisted (methods, standards)
  • Lung (diagnostic imaging)
  • Lung Diseases (diagnostic imaging)
  • Radiography, Thoracic (methods)
  • Reference Standards
  • Tomography, X-Ray Computed (methods)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: